Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...

Hot flashes may be one of the better-known indicators of menopause, but women may experience a wide range of symptoms as they enter this stage of life. Consider these tips to provide support and ...

In a real-world setting, the administration of oral semaglutide leads to a significant reduction in the urinary ...

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Most individuals with chronic kidney disease (CKD) are unaware of their disease, according to a KDIGO controversies conference on CKD prevention.

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...